The US Department of Justice issued subpoenas to two makers of generic pharmaceuticals last week, sparking an investigation into the industry and its competition. Now, report say, the case is already growing.
Generic drug makers Lannett and Impax Laboratories both confirmed they were contacted by the DOJ as part of a probe into their relationships with rivals. Impax added that the subpoena demanded one of its sales representatives to hand over documents and offer testimony about communication with rival drug makers.
The DOJ also revealed details of its investigation in a filing with the Securities and Exchange Commission.
Reports released earlier this year found that the price of some generic drugs charged to pharmacies has nearly doubled in the last year – leading prices for consumers to, in some cases, triple.
Connecticut’s Attorney General launched an investigation earlier this year into price hikes for congestive heart failure drug digoxin, a drug made by both Lannett and Impax, say reports.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI